Core Viewpoint - Central Garden (CENT) reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $0.94 per share, and showing an increase from $0.99 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 10.64%, with a significant prior quarter surprise of 800% when the company reported earnings of $0.21 per share against an expected loss of $0.03 [2] - Revenue for the quarter was $833.54 million, which fell short of the Zacks Consensus Estimate by 4.76% and decreased from $900.09 million year-over-year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates four times but has only topped revenue estimates once [3] Stock Performance and Outlook - Central Garden shares have declined approximately 11% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [4] - The company's earnings outlook is mixed, with current consensus EPS estimates of $1.32 for the upcoming quarter and $2.37 for the current fiscal year, alongside expected revenues of $1.01 billion and $3.23 billion respectively [8] Industry Context - The Consumer Products - Discretionary industry, to which Central Garden belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9] - The performance of Central Garden's stock may be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

Core Viewpoint - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.62 per share a year ago [1][2] Financial Performance - The company achieved revenues of $82.28 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26% and showing an increase from $78.03 million in the same quarter last year [3] - Inogen has surpassed consensus EPS estimates in all four of the last quarters [2][3] Stock Performance - Inogen shares have declined approximately 22.9% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current Zacks Rank for Inogen is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $91.8 million, and for the current fiscal year, it is -$1.41 on revenues of $352.81 million [8] - The trend of estimate revisions for Inogen is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

Group 1 - Super Micro Computer (SMCI) reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.30 per share, but down from $0.67 per share a year ago, representing an earnings surprise of 3.33% [1] - The company posted revenues of $4.6 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.13%, compared to $3.85 billion in the same quarter last year [2] - Super Micro has outperformed the S&P 500, gaining about 5.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.61 on revenues of $6.69 billion, and for the current fiscal year, it is $2.28 on revenues of $23.16 billion [7] - The Computer-Storage Devices industry, to which Super Micro belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, indicating potential challenges ahead [8] - The estimate revisions trend for Super Micro is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting it may underperform the market in the near future [6]

Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.21, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of 4.76% [1] - The company achieved revenues of $65.85 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26%, and showing a year-over-year increase from $49.57 million [2] - Over the last four quarters, Arcutis Biotherapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock has increased approximately 10.6% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $72.93 million, and for the current fiscal year, it is -$0.55 on revenues of $307.74 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Bioventus reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing an increase from $0.07 per share a year ago, indicating a positive earnings surprise of 33.33% [1] Financial Performance - The company achieved revenues of $123.88 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.72%, although this represents a decline from $129.46 million in the same quarter last year [2] - Over the last four quarters, Bioventus has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Bioventus shares have declined approximately 33.1% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $148.6 million, and for the current fiscal year, it is $0.66 on revenues of $565.01 million [7] - The estimate revisions trend for Bioventus is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

Core Insights - UL Solutions Inc. reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of 15.63% [1] - The company achieved revenues of $705 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.16% and up from $670 million year-over-year [2] - UL Solutions Inc. shares have increased approximately 20.2% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.47, with projected revenues of $769.66 million, and for the current fiscal year, the EPS estimate is $1.70 on revenues of $3.02 billion [7] - The estimate revisions trend for UL Solutions Inc. is mixed, leading to a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Business - Services industry, to which UL Solutions Inc. belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ABM Industries, is expected to report quarterly earnings of $0.88 per share, reflecting a year-over-year change of +1.2%, with revenues anticipated to be $2.08 billion, up 2.8% from the previous year [9]

Core Viewpoint - Crescent Energy (CRGY) reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.47 per share, and showing an increase from $0.46 per share a year ago, representing an earnings surprise of 19.15% [1][2] Financial Performance - The company posted revenues of $950.17 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.40%, and up from $657.47 million year-over-year [2] - Over the last four quarters, Crescent Energy has exceeded consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Crescent Energy shares have declined approximately 41% since the beginning of the year, compared to a decline of 3.3% for the S&P 500 [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates at $0.26 for the upcoming quarter and $1.66 for the current fiscal year, with revenues expected to be $898.17 million and $3.7 billion respectively [7] Industry Context - The Alternative Energy - Other industry, to which Crescent Energy belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Crescent Energy's stock performance [5]

Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...

Core Viewpoint - Standex International (SXI) reported quarterly earnings of $1.95 per share, exceeding the Zacks Consensus Estimate of $1.93 per share, and showing an increase from $1.75 per share a year ago, indicating a positive earnings surprise of 1.04% [1] Financial Performance - The company achieved revenues of $207.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33%, compared to $177.27 million in the same quarter last year [2] - Over the last four quarters, Standex has consistently surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance and Outlook - Standex shares have declined approximately 24.4% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.33 on revenues of $220.56 million, and for the current fiscal year, it is $7.86 on revenues of $785.88 million [7] - The estimate revisions trend for Standex is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which Standex belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - Blueprint Medicines reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of -76.19% [1] - The company posted revenues of $149.41 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.04%, but showing an increase from $96.12 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $171.35 million, and for the current fiscal year, it is -$1.01 on revenues of $728.21 million [7] 分组2 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Blueprint Medicines shares have increased by approximately 2.6% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The estimate revisions trend for Blueprint Medicines is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]